Read by QxMD icon Read

Diabetes & Metabolism

H B Østergaard, T Mandrup-Poulsen, G F N Berkelmans, Y van der Graaf, F L J Visseren, J Westerink
BACKGROUND: The haemoglobin glycation index (HGI) has been proposed as a marker of interindividual differences in haemoglobin glycosylation. Previous studies have shown a relationship between high HGI and risk of cardiovascular disease (CVD) in patients with diabetes. However, no studies have investigated the role of previous CVD in this association. METHODS: The study cohort comprised patients with type 2 diabetes mellitus (T2DM; n=1910) included in the Second Manifestations of Arterial Disease (SMART) study...
May 8, 2018: Diabetes & Metabolism
J Lepercq, C Le Ray, C Godefroy, L Pelage, D Dubois-Laforgue, J Timsit
AIM: This study assessed pregnancy outcomes in women with type 1 diabetes (T1D) over the last 15 years and identified modifiable factors associated with good perinatal outcomes. METHODS: Pregnancy outcomes were prospectively assessed in this cohort study of 588 singleton pregnancies (441 women) managed by standardized care from 2000 to 2014. A good perinatal outcome was defined as the uncomplicated delivery of a normally formed, non-macrosomic, full-term infant with no neonatal morbidity...
May 8, 2018: Diabetes & Metabolism
V Ponzo, L Gentile, R Gambino, R Rosato, I Cioffi, N Pellegrini, A Benso, F Broglio, M Cassader, S Bo
No abstract text is available yet for this article.
May 8, 2018: Diabetes & Metabolism
H Kahal, A Aburima, B Spurgeon, K S Wraith, A S Rigby, T Sathyapalan, E S Kilpatrick, K M Naseem, S L Atkin
AIM: Strict glycaemic control has been associated with an increased mortality rate in subjects with type 2 diabetes (T2DM). Here we examined platelet function immediately and 24hours following induced hypoglycaemia in people with type 2 diabetes compared to healthy age-matched controls. METHODS: Hyperinsulinaemic clamps reduced blood glucose to 2.8mmol/L (50mg/dl) for 1hour. Sampling at baseline; euglycaemia 5mmol/L (90mg/dl); hypoglycaemia; and at 24 post clamp were undertaken...
May 3, 2018: Diabetes & Metabolism
A Quintal, V Messier, R Rabasa-Lhoret, E Racine
The artificial pancreas combines a hormone infusion pump with a continuous glucose ontinuous glucose monitoring, supported by a dosing algorithm currently installed on the pump. It allows for dynamic infusions of insulin (and possibly other hormones such as glucagon) tailored to patient needs. For patients with type 1 diabetes the artificial pancreas has been shown to prevent more effectively hypoglycaemic events and hyperglycaemia than insulin pump therapy and has the potential to simplify care. However, the potential ethical issues associated with the upcoming integration of the artificial pancreas into clinical practice have not yet been discussed...
April 25, 2018: Diabetes & Metabolism
X-Q Li, D-Y Chang, M Chen, M-H Zhao
AIM: Emerging evidence has indicated a role of the complement system in the pathogenesis of diabetic nephropathy (DN), although the pathways of complement activation and their clinicopathological relevance in DN are as yet unclear. The present study aimed to investigate levels of various complement components in plasma and urine of DN patients, and their correlation with clinicopathological parameters. METHODS: A total of 68 biopsy-proven DN patients with plasma samples were recruited, including 50 patients who also had urine samples available...
April 16, 2018: Diabetes & Metabolism
E Sánchez, A Lecube, À Betriu, C Hernández, C López-Cano, L Gutiérrez-Carrasquilla, M Kerkeni, A Yeramian, F Purroy, R Pamplona, C Farràs, E Fernández, F Barbé, R Simó, M Hernández, F Rius, D Polanco, M S de la Torre, G Torres, P Godoy, M Portero-Otin, M Jové, L Colàs-Compàs, I Benabdelhak, E Miquel, M Ortega, J M Valdivielso, M Bermúdez, M Martínez-Alonso
No abstract text is available yet for this article.
April 13, 2018: Diabetes & Metabolism
B Balkau, M Metzger, F Andreelli, L Frimat, E Speyer, C Combe, M Laville, C Jacquelinet, S Briançon, C Ayav, Z Massy, R L Pisoni, B Stengel, D Fouque
AIM: To describe current practices of glucose-lowering treatments in people with diabetes and chronic kidney disease (CKD), the associated glucose control and hypoglycaemic symptoms, with an emphasis on sex differences. METHODS: Among the 3033 patients with CKD stages 3-5 recruited into the French CKD-REIN study, 645 men and 288 women had type 2 diabetes and were treated by glucose-lowering drugs. RESULTS: Overall, 31% were treated only with insulin, 28% with combinations of insulin and another drug, 42% with non-insulin glucose-lowering drugs...
April 6, 2018: Diabetes & Metabolism
E Papakonstantinou, M D Kontogianni, P Mitrou, E Magriplis, D Vassiliadi, T Nomikos, V Lambadiari, E Georgousopoulou, G Dimitriadis
BACKGROUND/OBJECTIVES: The study aimed to compare the effects of two eucaloric meal patterns (3 vs 6 meals/day) on glycaemic control and satiety in subjects with impaired glucose tolerance and plasma glucose (PG) levels 140-199mg/dL at 120min (IGT-A) or PG levels 140-199mg/dL at 120min and >200mg/dL at 30/60/90min post-oral glucose load on 75-g OGTT (IGT-B), or overt treatment-naïve type 2 diabetes (T2D). SUBJECTS/METHODS: In this randomized crossover study, subjects with IGT-A (n=15, BMI: 32...
April 6, 2018: Diabetes & Metabolism
J-S Yun, Y-M Park, K Han, S-A Cha, Y-B Ahn, S-H Ko
AIM: This study aimed to assess the association between body mass index (BMI) and the development of severe hypoglycaemia in patients with type 2 diabetes (T2D), using nationwide data for the entire South Korean population. METHODS: The association between BMI and severe hypoglycaemia was retrospectively examined from claims and National Health examination data registered between 2002 and 2015. A total of 1,366,692 subjects assigned clinical codes for T2D and prescribed antihypoglycaemic agents were included...
April 6, 2018: Diabetes & Metabolism
M P Hermans, S A Ahn, M F Rousseau
No abstract text is available yet for this article.
March 28, 2018: Diabetes & Metabolism
N H Kim, J Choi, N H Kim, K M Choi, S H Baik, J Lee, S G Kim
AIMS: This study examined whether dipeptidyl peptidase (DPP)-4 inhibitor use is beneficial or harmful to diabetic retinopathy (DR) compared with other glucose-lowering agents in patients with type 2 diabetes (T2D). METHODS: From a population-based cohort provided by the National Health Insurance Service in Korea, 67,743 adults with T2D were identified as having been treated with oral glucose-lowering agents between 2008 and 2013. Matching (1:1) was performed for two groups comparing ever-use (cases) and never-use (controls) of DPP-4 inhibitors (n=14,522 in each group)...
March 27, 2018: Diabetes & Metabolism
L Marchand, L Garnier, C Thivolet, M Nicolino, N Fabien
No abstract text is available yet for this article.
March 22, 2018: Diabetes & Metabolism
T-T Li, A-P Wang, J-X Lu, M-Y Chen, C-C Zhao, Z-H Tang, L-X Li, W-P Jia
AIM: As the prevalence and clinical characteristics of non-alcoholic fatty liver disease (NAFLD) are still unknown in ketosis-onset diabetes, the present study compared the characteristics of NAFLD in type 1 diabetes (T1D), ketosis-onset and non-ketotic type 2 diabetes (T2D) patients. METHODS: This cross-sectional study was performed with newly diagnosed Chinese patients with diabetes, including 39 T1D, 165 ketosis-onset and 173 non-ketotic T2D, with 30 non-diabetics included as controls...
March 21, 2018: Diabetes & Metabolism
F M Trovato, G F Martines, P Noto, G Mangano, L Malatino, G Carpinteri
No abstract text is available yet for this article.
March 15, 2018: Diabetes & Metabolism
L Monnier, C Colette, D R Owens
The assessment of glycaemic variability (GV) remains a subject of debate with many indices proposed to represent either short- (acute glucose fluctuations) or long-term GV (variations of HbA1c ). For the assessment of short-term within-day GV, the coefficient of variation for glucose (%CV) defined as the standard deviation adjusted on the 24-h mean glucose concentration is easy to perform and with a threshold of 36%, recently adopted by the international consensus on use of continuous glucose monitoring, separating stable from labile glycaemic states...
March 6, 2018: Diabetes & Metabolism
B M Mishriky, R J Tanenberg, K A Sewell, D M Cummings
AIMS: Our aim was to compare Sodium-glucose co-transporter 2 inhibitors (SGLT-2i) to Dipeptidyl peptidase-4 inhibitors (DPP-4i) as add-on therapy to metformin. METHODS: We searched for randomized trials comparing SGLT-2i to DPP-4i as add-on therapy to metformin in Type 2 diabetes.We pooled trials reporting outcomes between 12 and 26 weeks together while trials reporting results ≥52 weeks were pooled together. The primary outcomes were the change in haemoglobin A1c (A1c) at ≤26 and ≥52 weeks...
March 2018: Diabetes & Metabolism
Yen-Wei Pai, Ching-Heng Lin, I-Te Lee, Ming-Hong Chang
AIM: The relationship between glycaemic variability and painful diabetic peripheral neuropathy (PDPN) in patients with type 2 diabetes (T2D) is unclear. The aim of this study was to investigate whether variations in fasting plasma glucose (FPG), as represented by the coefficient of variation (CV), were associated with the risk of PDPN in patients with T2D. METHODS: This case-control, retrospective study was conducted at a tertiary care hospital in Taiwan. We enrolled adults with T2D from January 1 through October 31, 2013...
March 2018: Diabetes & Metabolism
K H Ha, S A Kim, Y M Lee, D J Kim, D H Lee
AIMS: This study investigated the association of persistent organic pollutants (POPs), an emerging new risk factor for type 2 diabetes and the metabolic syndrome, with the presence of opposite phenotypes of glucose and lipid metabolism among normal-weight Koreans of similar body composition. METHODS: Fifty subjects, randomly selected from an ongoing community-based cohort study, from two opposite phenotype groups - metabolically unhealthy normal weight (MUHNW) and metabolically healthy normal weight (MHNW) - were matched for waist circumference, visceral fat mass and demographic variables, then compared for serum concentrations of POPs...
March 2018: Diabetes & Metabolism
Y Matsubayashi, A Yoshida, H Suganami, H Ishiguro, M Yamamoto, K Fujihara, S Kodama, S Tanaka, K Kaku, H Sone
AIM: Hepatic insulin clearance (HIC) is important in regulating plasma insulin levels. Diminished HIC causes inappropriate hyperinsulinaemia, and both obesity and fatty liver (FL), which are known to decrease HIC, can be found either together in the same patient or on their own. The mechanism by which obesity reduces HIC is presumed to be mediated by FL. However, few reports have examined the role of FL in the relationship between obesity and HIC in type 2 diabetes (T2D) patients. Therefore, our study investigated the association of HIC with clinical factors, including insulin sensitivity indices, focusing on the presence or absence of FL and obesity in T2D patients...
March 2018: Diabetes & Metabolism
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"